1,495.00
+45(+3.10%)
Currency In JPY
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
1457
First IPO Date
March 08, 2004
| Name | Title | Pay | Year Born |
| Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D. | President, Chairman, Chief Executive Officer, Group Chief Financial Officer, Fisheries Business Officer & Chief Health Officer | 144.06M | 1958 |
| Satoshi Matsumoto | Managing Executive Officer & GM of Fisheries Division | 0 | 1968 |
| Toshiyuki Iwata | Managing Executive Officer, R/PR Division Manager & Sustainability Officer | 0 | N/A |
| Shinji Nitanda | Senior MD of Corporate Development & Corporate Tax Administration and Director | 0 | 1968 |
| Dr. Shu-Ichi Kanazashi M.D., Ph.D. | Managing Executive Officer, CMO and General Manager of TR Business Division | 0 | 1960 |
| Mr. Ken Takanashi CPA, MBA. | Executive Vice President of Group Corporate Management & Global Business & Director | 0 | 1964 |
| Dr. Hideshi Tsusaki DVM Ph.D. | Senior MD, President of Non-Clinical & Global Business Development and Director | 0 | 1967 |
| Kyomi Nagatoshi | Senior Managing Executive Officer, Head of General Affairs & Human Resources and Director | 0 | N/A |
| Terumasa Hirai | Managing Executive Officer & President and Representative Director of SNBL Ina Research Center | 0 | N/A |
| Fumihiko Makino | Senior Executive Officer, Financial Controller and GM of Finance & Accounting | 0 | N/A |
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.